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Background: Clinical practice guidelines have been developed to improve the quality of health care. However,
adherence to current monomorbidity-focused, mono-disciplinary guidelines may result in undesirable effects for
persons with several comorbidities, in adverse interactions between drugs and diseases, conflicting management
strategies, and polypharmacy. This is why new types of guidelines that address the problem of interacting medical
interventions and conditions in multimorbid patients are needed.
Discussion: Previous research projects investigated patterns of multimorbidity and were able to identify
combinations of the most prevalent chronic conditions, or clusters of comorbidities. These results represent
potential methodological starting points for the development of guidelines that account for multimorbidity. The
objective of these efforts is to identify frequent reasons for interactions and adverse events that may occur when
the current type of guideline is rigorously applied in multimorbid patients.
Summary: The epidemiologic approaches described above may help guideline developers as a kind of check list of
disease combinations that should systematically be considered during guideline development. Given the risk of
worse outcomes in a huge group of vulnerable patients, researchers, guideline developers, and funding institutions
should give first priority to the development of guidelines more appropriate for use in multimorbid persons.
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The patients encountered in general practice, particu-
larly those with multimorbidity, present a combination
of interacting problems, which make adherence to clinical
practice guidelines (CPG) and clinical decision making
very difficult when recommendations cumulate across
several conditions [1]. Nine out of ten patients seen in
general practice have more than one chronic condition
[2,3]. In 2005, Cynthia Boyd and colleagues illustrated the
limitations of the current type of CPGs. They aggregated
recommendations from relevant clinical guidelines for a
hypothetical case of a 79-year-old multimorbid woman
and ended up with 12 medications, prescribed in 19
partial doses, and a complicated nonpharmacological
regimen [4]. This hypothetical case shows that the* Correspondence: e.blozik@uke.de
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reproduction in any medium, provided the orcurrent way of designing CPGs is even associated with
undesirable effects for persons with several comorbidities,
and that adverse interactions between drugs and diseases,
conflicting management strategies, and polypharmacy
might result [5]. Polypharmacy exponentially increases the
risk of experiencing adverse drug-drug or drug-disease
interactions and is associated with adverse health outcomes
such as mortality, hospitalisation, poor adherence, and
geriatric syndromes (e.g. urinary incontinence, cognitive
impairment, falls) [6-8].
Since the publication of Boyd’s study, it is widely
acknowledged that elder persons and their health problems
are not adequately addressed in current mainly mono-
morbidity-focused and mono-disciplinary CPGs [5,9,10].
Various publications came to the conclusion that most
CPGs do not provide guidance on the management of
patients with comorbidities, especially for discordant
combinations, [11] and it has been claimed repeatedly
that CPGs should become explicit about the applicabilitytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Recently, Guthrie and colleagues suggested three strategies
for adaptation of CPGs to take account of multimorbidity:
1) cross-referencing between CPGs using electronic
delivery, 2) providing the suspected magnitude of benefits
and harms of medical interventions recommended in
CPGs, and 3) better using the existing evidence, e.g. by
modeling the effects comorbidities may have on benefits
and harms of treatments [15]. Although these adaptations
are necessary, we do not consider them to be sufficient.
For example, mere cross-referencing between CPGs would
become hardly manageable in the presence of more than
one comorbidity. The development of new CPGs that
include multimorbidity-specific information is desirable.
This article presents potential methodological starting
points for identifying relevant comorbidities that should be
taken into account during CPG development.
Discussion
Starting from epidemiologic data on prevalence of
comorbidities
Given the fact that there are an almost indefinite number
of possible disease combinations, [3] we suggest focusing
on the most prevalent combinations of chronic conditions
in multimorbid patients. The underlying assumption is
that this would help to identify a large part of discrepant
management strategies and interactions between treatments
and conditions.
Epidemiologic data from previous studies may help to
address either highly frequent combinations of chronic
medical conditions or combinations particularly difficult
to be handled [16]. For example, van den Bussche et al.
found that triads of the six most prevalent individual
chronic conditions (hypertension, hyperlipidemia, chronic
low back pain, diabetes mellitus, osteoarthritis and chronic
ischemic heart disease) cover nearly half on the elderly
multimorbid population [3]. When developing or reviewing
monomorbid CPGs, we propose to adapt the CPGs in the
sense of adding recommendations on how to proceed in
the management of the most prevalent associated
conditions. For example, a CPG on the management
of chronic ischemic heart disease should comment on
treatments for hypertension, hyperlipidemia, chronic low
back pain, diabetes mellitus, and/or osteoarthritis that
interfere with the index disease. The most prevalent
combinations of clinical conditions related to the index
disease would thus be covered by the CPG.
Other analyses used explorative techniques such as cluster
analysis [17] or factor analysis [16] to identify multimorbidity
patterns. For example, Schäfer et al. investigated a list of 46
ICD10-based chronic conditions and identified overlapping
clusters of 1) cardiovascular and metabolic diseases,
2) anxiety, depression, somatoform disorders and pain-
related morbidity, and 3) neuropsychiatric disorders [17].Based on such findings, CPGs might be supplemented
with information on frequent interactions between
treatments for diseases within one cluster. They could
also address problems that may occur in patients with
concurrent morbidities attributed to multiple clusters.
For example, CPGs for cardiovascular diseases that
recommend anticoagulants, antihypertensive, or lipid-
lowering drugs (cluster 1) should comment on what
should be done if a patient concurrently takes antide-
pressants, analgesics (to treat conditions included in
cluster 2), or neuropsychiatric drugs (to treat conditions
included in cluster 3) as interactions between these drugs
are frequent or potentially serious.
Applying clusters and triads using the example of Boyd’s
case
Using the 10 most frequent triads of comorbidities as a
basis for CPG development would mean that 5 of 9 con-
ditions of the theoretical Boyd’s case would have been
covered. In contrast, all of the comorbidities present in
Boyd’s case are included in either the cardiovascular and
metabolic disorder cluster or the anxiety, depression,
somatoform disorders and pain cluster. Conditions from
the neuropsychiatric disorders cluster are not present in
Boyd’s case. Thus, the triad model may be used as a kind
of checklist for frequent comorbidities, whereas the clus-
ter model may be helpful for grouping recommendations
related to comorbidities (Table 1).
Recommendations for CPG development
1. Increased applicability for multimorbid populations
to be an objective of the CPG
The CPG development team should explicitly agree
on the objective to create a guideline that ought to
be applicable in an as large as possible proportion of
the multimorbid population. We are convinced that
this would increase the awareness of the CPG
development team of potential problems associated
with concurrent comorbidities. It may also foster the
systematic inclusion of geriatric expertise in the
CPG development process.
2. Stratification of trial results by age and health
factors
Evidence for or against individual medical
interventions should be interpreted separately for
the relatively healthy patient population and the
subgroup of multimorbid patients. Specifically,
benefit in terms of survival of one intervention in
comparison to a potential increase in quality of life
or lower risk of adverse events of another
intervention may be weighed differently in the
multimorbid as compared to the relatively healthy
population and this fact may thus lead to different
Table 1 Comparison of the comorbidities mentioned in Boyd’s case and the triads (van den Bussche 2011) and cluster
(Schäfer 2010) model
Boyd 2005 [4] van den Bussche 2011 [3] Schäfer 2010 [17]
Hypertension Included in 9 triads Included in CMD cluster
Chronic heart failure Not included Included in CMD cluster
Stable angina Chronic ischemic heart disease included in 3 triads Chronic ischemic heart disease included in CMD cluster
Atrial fibrillation Not included Cardiac arrhythmias included in CMD cluster
Hypercholesterolemia Lipid metabolism disorder included in 6 triads Lipid metabolism disorder included in CMD cluster
Diabetes mellitus Included in 3 triads Included in CMD cluster
Osteoarthritis Included in 3 triads Included in ADS/P cluster
Chronic obstructive pulmonary disease Not included Included in ADS/P cluster
Osteoporosis Not included Included in ADS/P cluster
CMD: cardiovascular and metabolic disorder.
ADS/P: anxiety, depression, somatoform disorder, pain.
NPS: neuropsychiatric disorder.
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the relatively healthy patient population. Thus, existing
effectiveness data can be stratified by age group or
presence of certain morbidities, and guideline
developers could explicitly state if they were not able
to identify trial data related to older or multimorbid
populations. Relevant strata of comorbidities may be
detected by using the triad or cluster model.
3. Managing excessive complexity by focusing on
context specific CPGs
The fundamental challenge is to produce CPGs that
are not excessively long and complex. One solution
may be to develop context or problem specific
guidelines that provide information appropriate to
certain groups of patients (i.e. specific for the index
condition and a certain range of comorbidities).
Triads and clusters can be used as a basis for
developing case vignettes, which, in turn, help CPG
developers to address critical interactions between
diseases and therapies.
4. Cross-referencing to existing instruments
Additionally, there are a number of existing
initiatives that aim at reducing problems with
conflicting medications, such as the Medication
Appropriateness Index, [18] Beer’s criteria, [19] the
Priscus list, [20] the START/ STOPP initiative, [21]
or various computer-based drug interaction tools
[22]. These instruments have not been systematically
been considered in current CPGs, but CPG
developers may refer to such instruments to reduce
duplications and work load.
5. Involvement of all professional groups and patient
perspective
A broad range of disciplines and professions is
involved in the care for multimorbid patients. CPG
development teams are increasingly
multidisciplinary; however, the patient perspectiveand geriatric working principles such as focusing on
functional abilities, independence and quality of life
are not systematically included in the CPG
development process. The triad and cluster model
might help to identify the appropriate range of
disciplines and professions involved in the
management of the frequent comorbidities.
6. International collaboration
Given the fact that a large part of CPG work is done
by professional associations with a low budget and by
voluntary health experts, strategies for adapting CPGs
to multimorbidity should not exponentially increase
the work that needs to be done. Apart from focusing
on the most prevalent conditions, the complexity and
work load could be reduced if international
collaboration would be intensified. Clearly, for specific
health care settings or patient populations, it is
reasonable to interpret the evidence and to consent
recommendations on a local level. However, in
principle, synthesising the evidence is not specific to
individual health systems and may be exchanged
across countries. The EUnetHTA Joint Action [23]
and the Guidelines International Network (G-I-N)
[24], for example, are evidence that this type of
international cooperation and exchange is feasible.
Limitations and future research
Clearly, the existing epidemiologic research data related to
patterns of multimorbidity are not perfect. For example,
lists of chronic conditions used in previous research were
mainly not weighted for the impact of the listed condition
on quality of life, activities of daily living, or prognosis
[25]. Future research needs to go beyond studying the
prevalence of certain combinations, and should adjust
for the extent of comorbidities to compromise function,
quality of life, and life expectancy. As many diseases have
common risk factors and symptoms and might require
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be helpful to cluster therapeutic strategies as opposed
to conditions [26].
Limitations are also related to the existing evidence base
and to the way evidence in older persons is generated.
Current trials rarely include older, multimorbid persons and
insufficiently control for confounding factors such as greater
disease severity, place of residence, comorbid conditions, or
functional limitations [5]. However, drug regulatory author-
ities increasingly consider the problem of multimorbidity.
For example, in 2011 the European Medicines Agency
published its geriatric medicines strategy which states that
medicines should be studied appropriately in the older
population [27]. Specifically, trials are needed that include
elderly and comorbid populations, test complex interven-
tions such as appropriate prescribing measures and evaluate
relevant endpoints in these populations, e.g. functional out-
comes, quality of life, disability, or pain [28]. For weighing
risks and benefits of therapeutic interventions, future trials
should consequently report absolute effect estimates for
benefit and harm including the time period after which the
effect is expected to occur. For priority setting with respect
to comorbidities that need to be studied, triads and clusters
may also be helpful.
Summary
In the absence of specific recommendations for older,
multimorbid patients treatment decisions are mainly based
on expert opinion rather than on scientific evidence. The
epidemiologic approaches described above may constitute
a scientific basis for CPG developers to systematically
consider disease combinations that are highly prevalent in
the multimorbid population. The objective of these efforts
is to identify frequent reasons for interactions and adverse
events that may occur when the current type of CPG is
rigorously applied in multimorbid patients, which has
major implications for the weighting of benefits and harms
of recommended interventions. Case vignettes selected
based on epidemiologic data may present a practical link
between recommendations in CPGs and the heterogenetic
nature of multimorbidity in clinical practice. Given
these suggestions will increase the complexity of CPG de-
velopment, international collaboration and cross-reference
to existing instruments should be intensified to balance the
additional workload.
CPGs are not intended to replace the setting of diagnos-
tic, therapeutic, and preventive priorities on the individual
patient-doctor level. However, it is intolerable that provid-
ing health care in compliance with current CPGs might
result in worse outcomes and increased cost for a huge
group of vulnerable patients. Researchers, guideline devel-
opers, and funding institutions should give first priority to
developing such a new type of CPGs. This will require the
joint effort of all related societies and specialties.Abbreviations
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